Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is verapamil also a non-selective beta blocker?

M D Drici1, Y Jacomet, P Iacono

  • 1Department of Experimental and Clinical Pharmacology, Faculty of Medicine, Nice, France.

International Journal of Clinical Pharmacology, Therapy, and Toxicology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The cardiovascular safety of oral alitretinoin: a population-based cohort study involving 19 513 patients exposed to oral alitretinoin.

The British journal of dermatology·2021
Same author

Subthreshold grid laser versus intravitreal bevacizumab as second-line therapy for macular edema in branch retinal vein occlusion recurring after conventional grid laser treatment.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2014
Same author

Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis.

The British journal of ophthalmology·2014
Same author

Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score.

HIV medicine·2012
Same author

Evidence for anti-VEGF treatment of diabetic macular edema.

Ophthalmic research·2012
Same author

Subthreshold laser treatment for retinal arterial macroaneurysm.

The British journal of ophthalmology·2010
Same journal

Distribution of lidocaine and digoxin in heart tissues and aorta following intrapericardial administration.

International journal of clinical pharmacology, therapy, and toxicology·1993
Same journal

Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug.

International journal of clinical pharmacology, therapy, and toxicology·1993
Same journal

Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients.

International journal of clinical pharmacology, therapy, and toxicology·1993
Same journal

The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans.

International journal of clinical pharmacology, therapy, and toxicology·1993
Same journal

Is there a relationship between cytarabine pharmacokinetics and keratitis?--A case report.

International journal of clinical pharmacology, therapy, and toxicology·1993
Same journal

Effect of DL-sodium lactate infusion on excretion of purine bases and oxypurinol.

International journal of clinical pharmacology, therapy, and toxicology·1993
See all related articles

Verapamil, a calcium channel blocker, increases beta-2 adrenoceptor density in hypertensive patients, suggesting potential beta-blocking effects. This finding supports verapamil

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Adrenergic Receptor Research

Background:

  • Verapamil, a calcium channel blocker, is a common antihypertensive medication.
  • Its pharmacological actions may involve a degree of beta-adrenergic blockade.
  • Beta-2 adrenoceptor density changes are relevant to understanding drug mechanisms.

Purpose of the Study:

  • To investigate the effect of verapamil on beta-2 adrenoceptor density in hypertensive patients.
  • To compare verapamil's effects with captopril, an ACE inhibitor.
  • To explore the potential beta-blocking activity of verapamil.

Main Methods:

  • A double-blind, randomized study involving 40 patients with mild to moderate hypertension.
  • Patients received either verapamil (240 mg/day) or captopril (20 mg twice/day) for 30 days after a placebo period.

Related Experiment Videos

  • Lymphocytic beta-2 adrenoceptor density (Bmax) was measured before and after 15 days of treatment.

    • Main Results:

    • Both verapamil and captopril significantly reduced diastolic blood pressure after 30 days.
    • Verapamil treatment led to a significant up-regulation of beta-2 adrenoceptors after 15 days (39.5 to 58.5 fmol/mg protein).
    • Captopril did not significantly alter beta-2 adrenoceptor density, and dissociation constants remained unchanged for both drugs.

    Conclusions:

    • Verapamil treatment up-regulates beta-2 adrenoceptors in hypertensive patients.
    • This phenomenon supports the hypothesis that verapamil possesses beta-blocking properties.
    • The findings contribute to understanding the complex pharmacology of verapamil in hypertension management.